Subtype
Rectal Neoplasm
CI-CAN-00006564Explore in graph →
Non-malignant433 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006564Explore in graph →
Clinical trials
1,772 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06281405 | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer(TORCH-iTNT) | recruiting | Phase 2 | 192 | Fudan UniversityOTHER | 1 | Apr 3, 2026 |
| clinicaltrials |
| NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance | not yet recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT05515796 | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | completed | Phase 2 | 189 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02437656 | Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.(METCAP) | completed | Phase 2 | 60 | Centre Oscar LambretOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer(SCOTI) | recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07469306 | Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07458529 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer(NCRIT-PM9) | recruiting | Phase 2 | 50 | Seventh Medical Center of PLA General HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05731726 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06608537 | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer | completed | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07433673 | Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)(GAP Cemi) | recruiting | Phase 2 | 20 | Columbia UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07337876 | Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy(MARS) | recruiting | Phase 2 | 100 | University Hospital TuebingenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407465 | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA) | recruiting | Phase 2 | 42 | Gruppo Oncologico del Nord-OvestOTHER | 4 | Feb 17, 2026 | clinicaltrials |
| NCT05673772 | Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer(SOLAR) | active not recruiting | Phase 2 | 364 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03516708 | Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 1 / Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07397442 | Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 19 | Beijing Friendship HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402486 | A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer | not yet recruiting | Phase 2 | 20 | Siriraj HospitalOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07394192 | Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer(PKUCH- R11) | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07381400 | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) | not yet recruiting | Phase 2 | 128 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07381777 | XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients(IMMUNOSTAR) | not yet recruiting | Phase 2 | 270 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 83 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07068763 | Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer(mRCAT-E) | recruiting | Phase 2 | 52 | Sir Run Run Shaw HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | active not recruiting | Phase 2 | 29 | Baruch BrennerOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07314528 | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | not yet recruiting | Phase 2 | 42 | St. James's Hospital, IrelandOTHER | 0 | Jan 2, 2026 | clinicaltrials |
| NCT07297030 | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04417699 | SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer(SHORT) | completed | Phase 2 | 13 | Providence Health & ServicesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | suspended | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07160647 | The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)(Neo-IT) | active not recruiting | Phase 2 | 29 | Sir Run Run Shaw HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06493240 | Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer(NLCCRIT-LARC) | completed | Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01941641 | Colon Neoadjuvant FOLFOXIRI Study | active not recruiting | Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03997435 | FOLFOXIRI With or Without Intensification for Rectal Cancer | active not recruiting | Phase 2 | 72 | CCTUOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06640049 | A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China(China AZUR-1) | active not recruiting | Phase 2 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2026source: clinicaltrials